Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE Phase 3 trial of CYB003 in major depressive disorder
2024-519270-40-00Phase 3Authorised
- Sponsor
- Cybin Inc.
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of CYB003 in major depressive disorder (MDD) (3 arms), sponsored by Cybin Inc. Primary endpoint: Change from Baseline to Day 42 in MADRS total score. Planned start Oct 2025; status: authorised.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-519270-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519270-40-00.